This was obvious for LGMD patients in whom muscle immunohistochemical analyses and sequencing of few genes (mainly CAPN3, ANO5, and FHSD) were usually performed as a first-line, probably explaining the lower rate of positive diagnosis (40%) than the other studies (51.2% in the series by Savarese et al., [6]). This evidence concerns the gene CAPN3 and limb-girdle muscular dystrophy.